Oncotarget

Research Papers:

Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer

Muhammad Ary Zucha, Alexander T.H. Wu, Wei-Hwa Lee, Liang-Shun Wang, Wan-Wan Lin, Chiou-Chung Yuan and Chi-Tai Yeh _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:13255-13268. https://doi.org/10.18632/oncotarget.3658

Metrics: PDF 1583 views  |   HTML 1889 views  |   ?  


Abstract

Muhammad Ary Zucha1,2, Alexander T.H. Wu3,4, Wei-Hwa Lee5, Liang-Shun Wang6, Wan-Wan Lin1, Chiou-Chung Yuan7, Chi-Tai Yeh6,8

1 Graduate Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan

2 Department of Obstetrics and Gynecology, Gadjah Mada University-Sardjito Central Hospital, Yogyakarta, Indonesia

3 Graduate Institute of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan

4 Translational Research Laboratory, Cancer Center, Taipei Medical University Hospital, Taipei, Taiwan

5 Department of Pathology, Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan

6 Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

7 Obstetrics and Gynecology Department, Shuang-Ho Hospital, Taipei, Taiwan

8 Department of Medical Research and Education, Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan

Correspondence to:

Chi-Tai Yeh, email:

Chiou-Chung Yuan, email:

Keywords: ovarian cancer, cancer stem cell (CSC), spheroids, ibrutinib, Bruton’s tyrosine kinase (Btk), cisplatin

Received: December 14, 2014 Accepted: February 28, 2015 Published: March 26, 2015

Abstract

According to a Prognoscan database, upregulation of Bruton’s tyrosine kinase (Btk) is associated with low overall survival in ovarian cancer patients. We found that spheroids-forming ovarian cancer cell, which highly expressed cancer stem-like cell (CSC) markers and Btk, were cisplatin resistant. We next treated CSCs and non-CSCs by a combination of ibrutinib and cisplatin. We found that chemoresistance was dependent on Btk and JAK2/STAT3, which maintained CSC by inducing Sox-2 and prosurvival genes. We suggest that addition of ibrutinib to cisplatin may improve treatment outcome in ovarian cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3658